Multiple System Atrophy News and Research

RSS

Multiple-system atrophy (MSA) is a progressive neurological condition in which specific areas of the brain undergo neural degeneration. The three brain areas primarily affected are the brain stem, basal ganglia and cerebellum, portions of the brain that regulate bodily functions and motor control.

New platform can deliver gene therapy precisely to specific areas of the brain

A novel approach to gene therapy is improving lives in ways once thought impossible. Researchers at The Ohio State University Wexner Medical Center and College of Medicine have developed a new platform to deliver the gene therapy precisely to specific areas of the brain.

18 Apr 2024

New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.

3 Apr 2024

Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective

The positivity rate of cutaneous phosphorylated alpha-synuclein protein (P-SYN) deposition among individuals with dementia.

26 Mar 2024

Skin biopsy test shows promise in diagnosing Parkinson's disease and synucleinopathies

In a paper published in the Journal of the American Medical Association (JAMA), neurologists at Beth Israel Deaconess Medical Center (BIDMC) showed that a simple skin biopsy test detects an abnormal form of alpha-synuclein, the pathological hallmark of Parkinson's disease and the subgroup of neurodegenerative disorders known as synucleinopathies, at high positivity rates.

20 Mar 2024

Groundbreaking study unveils new insights into neurodegenerative disorder symptoms

Identification of clinical disease trajectories in neurodegenerative disorders with natural language processing.

14 Mar 2024

Cytokine interferon-gamma can be a disease-modifying therapeutic target in multiple system atrophy

Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain.

12 Feb 2024

New test detects Parkinson's disease before symptoms appear

In the development of Parkinson's disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms.

8 Jan 2024

Sex-specific brain immunometabolism differences may underlie increased Alzheimer's risk in women

Cleveland Clinic researchers analyzed genes and brain tissue of patients with Alzheimer's and found that differences in brain immunometabolism – the interactions between the immune system and the ways cells create energy – may contribute to women's increased risk for the disease and its severity.

21 Nov 2023

Dr. Anthony Lang reveals new model for studying Parkinson’s disease at the 26th World Congress of Neurology

During a plenary lecture at the 26th World Congress of Neurology, Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson’s disease. This new approach will help researchers investigate biological aspects of the disease that may be detectable many years before symptoms begin to show.

20 Oct 2023

Novel assay for identifying individuals with synucleinopathies using serum samples

Synucleinopathies are a group of neurodegenerative diseases caused by the abnormal accumulation α-synuclein, a protein normally found in the brain and neurons. Incorrect folding of α-synuclein leads to formation of 'seeds', which attract more α-synuclein proteins to form larger clumps.

29 May 2023

Key steps for diagnosis and management of orthostatic tachycardia after COVID-19

A recent article discussed the prevalence, assessment, and practice pointers for the management of presentations of tachycardia among long COVID.

10 Mar 2023

Exploring two small molecules for the disintegration of alpha-synuclein fibrils

In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the capability of two small molecules of disintegrating alpha-synuclein fibrils.

13 Feb 2023

In vivo imaging of α-synuclein aggregates in the brains of living patients with multiple system atrophy

α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain.

30 Aug 2022

UT Southwestern researchers reveal the physical mechanism behind a neurological autoimmune disease

Using UT Southwestern's Cryo-Electron Microscopy Facility, researchers for the first time have captured images of an autoantibody bound to a nerve cell surface receptor, revealing the physical mechanism behind a neurological autoimmune disease.

11 Jul 2022

New research reveals a potent weapon against Parkinson's disease

Neurodegenerative diseases damage and destroy neurons, ravaging both mental and physical health. Parkinson's disease, which affects over 10 million people worldwide, is no exception.

11 May 2022

New deep learning method aids in the accurate diagnosis of parkinsonian diseases

A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published ahead of print by The Journal of Nuclear Medicine.

21 Apr 2022

$35.1 million US grant focuses on investigating sleep disorder linked to neurodegeneration

People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary ball, or try to run from an illusory assailant.

5 Oct 2021

Discovery points toward a new strategy for treating Parkinson's disease

University of Utah Health scientists have identified a molecule that slows cells' production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson's disease.

23 Sep 2021

Discovery points toward a new strategy for treating Parkinson’s disease

University of Utah Health scientists have identified a molecule that slows cells’ production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s disease.

21 Sep 2021

Nasal drugs show success in slowing Parkinson's disease progression in mice

Potential new treatments for Parkinson's disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.